Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andersson

Showing results (21-30 of 95) with videos related to

Pageof 10
Sort By:
Cancer Treatment and Research Communications|January 2, 2021
Heart rate variability and vibration perception threshold to assess chemotherapy-induced neuropathy in women with breast cancer - a systematic reviewSimone Diedrichsen Marstrand, Kristian Buch-Larsen, Michael Andersson, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|June 14, 2021
Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational studyKristian Buch-Larsen, Niklas Rye Jørgensen, Lars Thorbjørn Jensen, et al.
Cancer Medicine|June 24, 2022
Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic reviewDjordje Marina, Åse Krogh Rasmussen, Kristian Buch-Larsen, et al.
Breast Cancer (Tokyo, Japan)|December 15, 2015
Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort studyCamilla Praestegaard, Susanne K Kjaer, Michael Andersson, et al.
Breast (Edinburgh, Scotland)|March 23, 2020
Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patientsThomas Christensen, Tobias Berg, Lise Birk Nielsen, et al.
Cancer Treatment and Research Communications|October 31, 2025
Impact of aromatase inhibitors on thyroid function in postmenopausal women with early-stage breast cancer: a prospective controlled studyDjordje Marina, August Nielsen, Kristian Buch-Larsen, et al.
Breast (Edinburgh, Scotland)|November 13, 2020
Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG)Tobias Berg, Maj-Britt Jensen, Erik H Jakobsen, et al.
BMC Cancer|September 19, 2021
Cardiovascular disease in women with breast cancer - a nationwide cohort studyMarie Jakobsen, Christophe Kolodziejczyk, Morten Sall Jensen, et al.
Breast Cancer Research and Treatment|June 28, 2018
Mortality after contralateral breast cancer in DenmarkRikke Langballe, Kirsten Frederiksen, Maj-Britt Jensen, et al.
Breast Cancer : Basic and Clinical Research|April 1, 2022
First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCGAlan Celik, Tobias Berg, Lise Birk Nielsen, et al.
Pageof 10

Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
Cancer Treatment and Research Communications|January 2, 2021
Heart rate variability and vibration perception threshold to assess chemotherapy-induced neuropathy in women with breast cancer - a systematic reviewSimone Diedrichsen Marstrand, Kristian Buch-Larsen, Michael Andersson, et al.
Scandinavian Journal of Clinical and Laboratory Investigation|June 14, 2021
Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational studyKristian Buch-Larsen, Niklas Rye Jørgensen, Lars Thorbjørn Jensen, et al.
Cancer Medicine|June 24, 2022
Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic reviewDjordje Marina, Åse Krogh Rasmussen, Kristian Buch-Larsen, et al.
Breast Cancer (Tokyo, Japan)|December 15, 2015
Risk of skin cancer following tamoxifen treatment in more than 16,000 breast cancer patients: a cohort studyCamilla Praestegaard, Susanne K Kjaer, Michael Andersson, et al.
Breast (Edinburgh, Scotland)|March 23, 2020
Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patientsThomas Christensen, Tobias Berg, Lise Birk Nielsen, et al.
Cancer Treatment and Research Communications|October 31, 2025
Impact of aromatase inhibitors on thyroid function in postmenopausal women with early-stage breast cancer: a prospective controlled studyDjordje Marina, August Nielsen, Kristian Buch-Larsen, et al.
Breast (Edinburgh, Scotland)|November 13, 2020
Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG)Tobias Berg, Maj-Britt Jensen, Erik H Jakobsen, et al.
BMC Cancer|September 19, 2021
Cardiovascular disease in women with breast cancer - a nationwide cohort studyMarie Jakobsen, Christophe Kolodziejczyk, Morten Sall Jensen, et al.
Breast Cancer Research and Treatment|June 28, 2018
Mortality after contralateral breast cancer in DenmarkRikke Langballe, Kirsten Frederiksen, Maj-Britt Jensen, et al.
Breast Cancer : Basic and Clinical Research|April 1, 2022
First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCGAlan Celik, Tobias Berg, Lise Birk Nielsen, et al.
Pageof 10